- FDA advisory panel to consider OTC status of NSAIDs
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- FDA approves combination of two GSK drugs for skin cancer
- FDA recommends health professionals prescribe no more than 325 mg of acetaminophen per dose
- Prestige Brands solution to pediatric overdosing — unique squeezable, single-dose APAP packet
PITTSBURGH The Food and Drug Administration has approved a generic arthritis treatment made by Mylan, the drug maker said Wednesday.
The FDA approved nabumetone tablets, a treatment for osteoarthritis and rheumatoid arthritis, in the 500 mg and 750-mg strengths.
Nabumetone tablets had sales of $68 million during the 12-month period ended in March, according to IMS Health. SmithKline Beecham, a predecessor company to GlaxoSmithKline, originally sold nabumetone tablets under the brand name Relafen, though Relafen no longer is available.